Structure-Based Drug Design: Multi-Arm PEG/Peptidomimetic Conjugate Inhibitors of DR6/APP Interaction Block Hematogenous Tumor Cell Extravasation (Adv. Sci. 11/2021)

In article number 2003558 by Hongze Liao, Houwen Lin, Yourong Duan, and co‐workers, first class of APP/DR6 inhibitor, polymer–peptidomimetic PEG‐tAHP‐DRI, are developed by utilizing three rationaldesigned screening strategies, which demonstrate promising anti‐hematogenous metastatic activity by inhibiting the binding of amyloid precursor protein (APP) and death receptor 6 (DR6) as well as blocking the necroptosis of vascular endothelial cells induced by tumors cells.